With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
Viagra, the wildly successful erectile dysfunction pill, faces challenges from a generic version that will launch next year.
Eli Lilly and Co. (NYSE: LLY) is watching its shares make a decent gain on Wednesday following a U.S. Food and Drug Administration (FDA) vote. The FDA Advisory Committee voted 12-11 that…
Chris Lange With the market pushing through to all-time highs, we are looking for solid total return ideas for investors. Total return is one of the best ways to help improve the chances for…
The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two cents on companies making presentations at the conference.
Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology (ASCO) annual meeting, and it has issued a report on what it…
The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Volumes tend to dry up in the summer as traders and investors go on vacation, making it all that much easier for the short-sellers to exploit headline and market risk.
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these…
With a flight to cash hardly workable for most investors, and Treasury bonds seemingly very rich, quality low-volatility dividend stocks make the most sense in for uncertain times.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Bats Global Markets, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer and SolarCity.
Eli Lilly is set to release its first-quarter earnings report before the markets open on Tuesday.
Chris Lange Long-term growth investors looking for a degree of safety and value should consider some of these outstanding companies. While the sentiment may be less than stellar now, massive drug pricing changes anytime…
In a new research report, Credit Suisse highlighted some companies on its U.S. Focus List that stand to have the most potential price return.
